Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 11/20 | 1.00 |
| ▸ | KDR | P35968 | 8/20 | 1.00 |
| ▸ | FLT1 | P17948 | 6/20 | 1.00 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4771261 | 1.00 | TEK (1.00) | TEKKDRFLT1GRM4HDAC6 | |
| SCHEMBL4769197 | 0.84 | TEK (1.00) | TEKKDRFLT1GRM4HDAC6 | |
| SCHEMBL4769183 | 0.84 | TEK (1.00) | TEKKDRFLT1GRM4HDAC6 | |
| SCHEMBL4774681 | 0.81 | TEK (1.00) | TEKKDRFLT1GRM4HDAC6 | |
| SCHEMBL4774678 | 0.81 | TEK (1.00) | TEKKDRFLT1GRM4HDAC6 | |
| SCHEMBL4771720 | 0.81 | TEK (1.00) | TEKKDRFLT1GRM4HDAC6 | |
| SCHEMBL4771725 | 0.81 | TEK (1.00) | TEKKDRFLT1GRM4HDAC6 | |
| SCHEMBL4774618 | 0.73 | TEK (0.56) | TEKKDRFLT1MAPTNPC1 | |
| SCHEMBL4769255 | 0.71 | TEK (1.00) | TEKKDRFLT1GRM4HDAC6 | |
| SCHEMBL4769246 | 0.71 | TEK (1.00) | TEKKDRFLT1GRM4HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575963-B1 | ANTI-ANGIOGENETIC THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2008-05-07 | — | — | EP | disclosed |
| US-20060069109-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069109-A1 | Therapeutic agents | TIE1, TEK, KDR | TEK 2/4885KDR 3/4885FLT1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.